Cancer Institute A national cancer institute
designated cancer center

Yueh-hsiu Chien

Publication Details

  • CD4 augments the response of a T cell to agonist but not to antagonist ligands IMMUNITY Hampl, J., Chien, Y. H., DAVIS, M. M. 1997; 7 (3): 379-385


    The recognition of peptide variants by the T cell receptor (TCR) has revealed a wide range of possible responses. Here, using a series of CD4+ and CD4- variants of the same T cell hybridoma, we find that while the expression of CD4 converts weak agonists into full agonists, none of the antagonist peptides are efficiently recognized as agonists. Furthermore, in antagonist assays, little difference can be seen in the response of CD4+ and CD4- T cells. Together with previous work showing a marked difference in stability between TCR binding to agonist versus antagonist ligands, these data suggest that CD4 engagement occurs after a TCR-peptide/MHC complex has formed and that it requires a certain minimal half-life of the ternary complex to be fully engaged in signaling.

    View details for Web of Science ID A1997XY83000007

    View details for PubMedID 9324358

Stanford Medicine Resources:

Footer Links: